Please login to the form below
Bendectin
This page shows the latest Bendectin news and features for those working in and with pharma, biotech and healthcare.
FDA slams Kardashian West's Instagram drug promotion
Doxylamine succinate and pyridoxine hydrochloride was originally marketed as Bendectin in the US from 1956, but was pulled from the market in 1983 after its makers Merrell Dow faced several legal
Latest news
-
FDA approves return of morning sickness drug for pregnant women
Regulator confirms safety of Diclegis – formerly known as Bendectin. Photo: Diclegis 10mg (PRNewsFoto/Duchesnay USA). ... Doxylamine succinate and pyridoxine hydrochloride was originally marketed as Bendectin in the US from 1956, but was pulled from
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Featured jobs
- Digital Associate Director - Medcomms
-
£65000 - £80000 per annum
-
Account Director, Medical Education
-
Salary TBC
- Account Director, Healthcare Communications
-
Salary TBC
-
Experienced medical editor
-
Competitive salary and bonus scheme
-
Account Manager (PR)
-
Great Benefits
- Group Director of Medical Affairs and Scientific Strategy, Medic...
-
Substantial six figure package
- Senior Medical Writer, MedComms Agency
-
Salary TBC
-
Scientific Director
-
£60000 - £85000 per annum, Benefits: Bonus, pension, subsidised gym and much more
-
Senior External Communications Lead
-
£Competitive Salary
-
Account Manager
-
£Competitive Salary
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Account director
-
Competitive salary and bonus scheme
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Account Director
-
£Competitive Salary
-
Publications director
-
Competitive salary and bonus scheme
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
Subscribe to our email news alerts
- Novo Nordisk awakens its ‘Sleeping Beauty’
- BMS unveils long-term results for Opdivo in kidney cancer
- Categories - Communiqué Awards
- Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD
- US backs Sanofi’s ‘fast-track’ coronavirus vaccine
- Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD
- Introducing Nucleus POLAR™, a state-of-the-art external expert search engine and engagement management tool
- GSK pays $50m upfront to tap Immatics’ cell therapy platform
- Researchers discover new antibiotic using AI
- Bedrock Group celebrates a trio of new hires
- Tocagen merges with Forte Biosciences after brain cancer fail
- Immutep spikes on trial of its LAG-3 drug with Keytruda
PMHub
Oxford University Press
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...
Latest intelligence
- Novo Nordisk awakens its ‘Sleeping Beauty’
- Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
- How will the Tories’ historic win shape the NHS?
- Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
- CSR 'Christmas Spirit' 2019
- OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...
Quick links
Infographics
